KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Current Leases (2020 - 2025)

Novavax has reported Current Leases over the past 9 years, most recently at $12.4 million for Q4 2025.

  • Quarterly results put Current Leases at $12.4 million for Q4 2025, up 76.7% from a year ago — trailing twelve months through Dec 2025 was $12.4 million (up 76.7% YoY), and the annual figure for FY2025 was $12.4 million, up 76.7%.
  • Current Leases for Q4 2025 was $12.4 million at Novavax, up from $5.0 million in the prior quarter.
  • Over the last five years, Current Leases for NVAX hit a ceiling of $130.5 million in Q4 2021 and a floor of $953000.0 in Q2 2023.
  • Median Current Leases over the past 5 years was $11.0 million (2024), compared with a mean of $44.8 million.
  • Biggest five-year swings in Current Leases: plummeted 99.23% in 2023 and later surged 889.19% in 2024.
  • Novavax's Current Leases stood at $130.5 million in 2021, then crashed by 79.17% to $27.2 million in 2022, then increased by 3.39% to $28.1 million in 2023, then crashed by 75.07% to $7.0 million in 2024, then soared by 76.7% to $12.4 million in 2025.
  • The last three reported values for Current Leases were $12.4 million (Q4 2025), $5.0 million (Q3 2025), and $5.6 million (Q2 2025) per Business Quant data.